Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kezar Life Sciences (KZR) EBITDA Margin (2021 - 2025)

Historic EBITDA Margin for Kezar Life Sciences (KZR) over the last 5 years, with Q2 2025 value amounting to 4834.11%.

  • Kezar Life Sciences' EBITDA Margin fell 9970700.0% to 4834.11% in Q2 2025 from the same period last year, while for Jun 2025 it was 11670.11%, marking a year-over-year increase of 133995800.0%. This contributed to the annual value of 1591.77% for FY2023, which is N/A changed from last year.
  • Latest data reveals that Kezar Life Sciences reported EBITDA Margin of 4834.11% as of Q2 2025, which was down 9970700.0% from 5080.4% recorded in Q1 2025.
  • In the past 5 years, Kezar Life Sciences' EBITDA Margin registered a high of 8869.81% during Q4 2021, and its lowest value of 364.67% during Q3 2023.
  • For the 5-year period, Kezar Life Sciences' EBITDA Margin averaged around 5601.58%, with its median value being 5964.43% (2022).
  • In the last 5 years, Kezar Life Sciences' EBITDA Margin soared by 9557800bps in 2023 and then crashed by -11257100bps in 2024.
  • Kezar Life Sciences' EBITDA Margin (Quarter) stood at 8869.81% in 2021, then plummeted by -32bps to 6001.1% in 2022, then crashed by -106bps to 364.67% in 2023, then soared by 1699bps to 5831.17% in 2024, then dropped by -17bps to 4834.11% in 2025.
  • Its EBITDA Margin was 4834.11% in Q2 2025, compared to 5080.4% in Q1 2025 and 5831.17% in Q2 2024.